Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034489 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00034489: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00034489 is a Phase 2 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034489, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.
Interventions
- DRUG pemetrexed
- DRUG gemcitabine
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00034489 record still lists
NCT00034489 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which pemetrexed is the first listed.
NCT00034489 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00034489 about?
NCT00034489 is a clinical study titled "A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.". This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.
What is the current status of trial NCT00034489?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00034489?
The interventions under investigation include: pemetrexed (DRUG), gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00034489?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.